Clinical Trials Directory

Trials / Terminated

TerminatedNCT03011749

Value of FLT PET/CT in Radium-223 Therapy of mCRPC Patients

Value of FLT PET/CT in Radium-223 Therapy of Patients With Metastatic Castration-resistant Prostate Cancer

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
6 (actual)
Sponsor
Rigshospitalet, Denmark · Academic / Other
Sex
Male
Age
Healthy volunteers
Not accepted

Summary

The aim of the study is to investigate whether positron emission tomography (PET) using the tracer 18F-Fluorothymidine (FLT) can provide information on proliferative activity in bone marrow of patients receiving Radium 223 therapy and potentially be a predictive marker of hematological toxicity

Conditions

Interventions

TypeNameDescription
OTHERFLT PET/CTFLT PET/CT before first series of Radium-223 and after 2 series

Timeline

Start date
2017-01-01
Primary completion
2018-02-01
Completion
2018-02-01
First posted
2017-01-05
Last updated
2019-09-12

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT03011749. Inclusion in this directory is not an endorsement.

Value of FLT PET/CT in Radium-223 Therapy of mCRPC Patients (NCT03011749) · Clinical Trials Directory